Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Description & Pharmacodynamics FOXO4-DRI is a modified peptide derived from the Forkhead box protein O4 (FOXO4), which plays a crucial role in cellular stress response and longevity pathways (1, 8)
This central mechanism of action distinguishes PT-141 from peripheral vasodilators, making it particularly valuable for addressing desire-related dysfunction rather than solely physical arousal deficits
(2022) Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation Biomedicines, 2022 Oct 25;10(11):2696
Drugs that raise HDL (niacin, CETP inhibitors) were tried as cardiovascular therapies in major trials
Researchers should note that PT-141 produces a transient, dose-dependent increase in blood pressure it must not be used by individuals with cardiovascular disease, uncontrolled hypertension, or high cardiovascular risk, and must not be self-administered or used outside a controlled laboratory environment
GLP-1 agonists like semaglutide and tirzepatide do not contaminate blood or pose a direct risk to transfusion recipients
US$ 24.21
US$ 21.23
US$ 21.89
US$ 21.51
US$ 24.80
